

Antitumor agent-28 Biochemical

Antitumor agent-28

CATALOG #
AAA228106


PRODUCT SYNONYMS

Antitumor agent-28; Antitumor agent-28 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2097499-67-5
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	Antitumor agent-28 inhibits ataxia telangiectasia mutated (ATM; IC 50 =7.6 nM; HT29 cells), ataxia telangiectasia and Rad3-related protein (ATR; IC 50 =18 uM; HT29 cells), PI3Ka (IC 50 =0.24 uM; BT474 cells). Antitumor agent-28 does not inhibit mTOR in MDA-MB-468 cells[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
S,R,S)-AHPC-Me-CO-CH₂-PEG₃-NH₂, CAS 2409538-69-6



Structure
S,R,S)-AHPC-Me-CO-CH₂-PEG₃-NH₂, CAS 2409538-69-6

ADDITIONAL INFORMATION

Related Product Information for Antitumor agent-28 biochemical	Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity.
References	1. Mar? A Maneiro, et al. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4. ACS Chem Biol. 2020 Jun 19;15(6):1306-1312.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.